Breast cancer risk in the WHI study: The problem of obesity

Maturitas

Volumn 51, Issue 1, 2005, Pages 83-97

  Kuhl, Herbert ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Breast cancer risk; Hormone replacement therapy; Hyperinsulinemia; Obesity; Postmenopause

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL PLUS NORETHISTERONE; GESTAGEN; HORMONE; INSULIN; MEDROXYPROGESTERONE ACETATE; METFORMIN; ORAL CONTRACEPTIVE AGENT; SEX HORMONE; TIBOLONE;

ALCOHOL CONSUMPTION; BENIGN TUMOR; BIRTH; BODY MASS; BREAST CANCER; BREAST TUMOR; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TISSUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFERENCE PAPER; CYANOCOBALAMIN DEFICIENCY; DATA ANALYSIS; DENSITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EPIDEMIOLOGICAL DATA; ESTROGEN THERAPY; GASTROINTESTINAL SYMPTOM; HEREDITY; HIGH RISK POPULATION; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFESTYLE; LOW DRUG DOSE; MAMMOGRAPHY; MENARCHE; MENOPAUSAL SYNDROME; MENOPAUSE; METABOLIC SYNDROME X; NUTRITION; OBESITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PROGNOSIS; PROVOCATION TEST; REGULATORY MECHANISM; REPRODUCTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING; STIMULATION; TRANSVAGINAL ECHOGRAPHY; TREATMENT INDICATION; TUMOR GROWTH;

BODY WEIGHT; BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; LIFE STYLE; MALE; MENOPAUSE; OBESITY; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 18844398050     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.02.018     Document Type: Conference Paper

References (104)

1. G. Kvale Reproductive factors in breast cancer epidemiology Acta Oncol 31 1992 187 194
2. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease Lancet 360 2002 187 195
3. M. Garland, D.J. Hunter, and G.A. Colditz Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of US women Am J Epidemiol 147 1998 636 643
4. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies with 52705 women with breast cancer and 108411 women without breast cancer Lancet 350 1997 1047 1059
5. B.S. Hulka, and P.G. Moorman Breast cancer: hormones and other risk factors Maturitas 42 Suppl 1 2002 95 108
6. L.M. Morimoto, E. White, and Z. Chen Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States) Cancer Causes Contr 13 2002 741 751
7. H.O. Adami, G. Adams, and P. Boyle Breast cancer etiology Int J Cancer Suppl 5 1990 22 39
8. M. Ewertz, S.W. Duffy, and H.O. Adami Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries Int J Cancer 46 1990 597 603
9. G.A. Colditz, and B. Rosner Cumulative risk of breast cancer to age 70 according to risk factor status: data from the nurses' health study Am J Epidemiol 152 2000 950 964
10. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies Lancet 347 1996 1713 1727
11. P.A. Marchbanks, J.A. McDonald, and H.G. Wilson Oral contraceptives and the risk of breast cancer N Engl J Med 346 2002 2025 2032
12. Writing Group for the Women's Health initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial JAMA 288 2002 321 333
13. W.Y. Chen, G.A. Colditz, and B. Rosner Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer Ann Intern Med 137 2002 798 804
14. J.A. Kaye, C.R. Meier, A.M. Walker, and H. Jick Statin use, hyperlipidaemia, and the risk of breast cancer Br J Cancer 86 2002 1436 1439
15. McTiernan, C. Kooperberg, and E. White Recreational physical activity and the risk of breast cancer in postmenopausal women (WHI cohort study) JAMA 290 2003 1331 1336
16. E.S. Schernhammer, F. Laden, and F.E. Speizer Rotating night shifts and risk of breast cancer in women participating in the nurses' health study J Natl Cancer Inst 93 2001 1563 1568
17. C.M. Velicer, S.R. Heckbert, J.W. Lampe, J.D. Potter, C.A. Robertson, and S.H. Taplin Antibiotic use in relation to the risk of breast cancer JAMA 291 2004 827 835
18. S. Hulley, C. Furberg, and E. Barrett-Connor Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II) JAMA 288 2002 58 66
19. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial JAMA 291 2004 1701 1712
20. H. Kuhl Effects of estrogen-only treatment in postmenopausal women (letter) JAMA 292 2004 683
21. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
22. C. Magnusson, J.A. Baron, and N. Correia Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy Int J Cancer 81 1999 339 344
23. R.T. Chlebowski, Hendrix, and R.D. Langer Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women JAMA 289 2003 3243 3253
24. T.L. Bush, M. Whiteman, and J.A. Flaws Hormone replacement therapy and breast cancer: a qualitative review Obstet Gynecol 98 2001 498 508
25. R.K. Ross, A. Paganini-Hill, P.C. Wan, and M.C. Pike Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J Natl Cancer Inst 92 2000 328 332
26. C. Schairer, J. Lubin, R. Rroisi, S. Sturgeon, L. Brinton, and R. Hoover Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 2000 485 491
27. V. Kirsh, and N. Kreiger Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada Cancer Causes Contr 13 2002 583 590
28. J.V. Porch, I.M. Lee, and N.R. Cook Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United states) Cancer Causes Contr 13 2002 847 854
29. J.R. Daling, K.E. Malone, and D.R. Doody Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma Cancer 95 2002 2455 2464
30. L.K. Weiss, R.T. Burkman, and K.L. Cushing-Haugen Hormone replacement therapy regimens and breast cancer risk Obstet Gynecol 100 2002 1148 1158
31. C.L. Chen, N.S. Weiss, and P. Newcomb Hormone replacement therapy in relation to breast cancer JAMA 287 2002 734 741
32. H. Jernström, P.O. Bendahl, J. Lidfeldt, C. Nerbrand, C.D. Agardh, and G. Samsioe A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden) Cancer Causes Contr 14 2003 673 680
33. C.I. Li, K.E. Malone, and P.L. Porter Relationship between long durations and different regimens of hormone therapy and risk of breast cancer JAMA 289 2003 3254 3263
34. K. Bakken, E. Asaker, A.E. Eggen, and E. Lund Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer Study Int J Cancer 112 2004 130 134
35. C. Stahlberg, A.T. Pedersen, and E. Lynge Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe Int J Cancer 109 2004 721 727
36. C. Stahlberg, A.T. Pedersen, and Z.J. Andersen Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy Br J Cancer 91 2004 644 650
37. A. Tjonneland, J. Christensen, and B.L. Thomsen Hormone replacement therapy in relation to breast carcinoma incidence rate ratios Cancer 100 2004 2328 2337
38. G.A. Colditz, B.A. Rosner, W.Y. Chen, M.D. Holmes, and S.E. Hankinson Risk factors for breast cancer according to estrogen and progesterone receptor status J Natl Cancer Inst 96 2004 218 228
39. W.C. Black, and H.G. Welch Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy N Engl J Med 328 1993 1237 1243
40. S. Menard, P. Casalini, R. Agresti, S. Pilotti, and A. Balsari Proliferation of breast carcinoma during menstrual phases Lancet 352 1998 148 149
41. C.S. Potten, R.J. Watson, and G.T. Williams The effect of age and menstrual cycle upon proliferative activity of the normal human breast Br J Cancer 58 1988 163 170
42. L.J. Hofseth, A.M. Raafat, J.R. Osuch, D.R. Pathak, C.A. Slomski, and S.Z. Haslam Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast J Clin Endocrinol Metab 84 1999 4559 4565
43. J.M. Cline, G. Soderqvist, E. von Schoultz, L. Skoog, and B. von Schoultz Effects of hormone replacement therapy on mammary gland of surgically postmenopausal cynomolgus macaques Am J Obstet Gynecol 174 1996 93 100
44. J.M. Cline, T.C. Register, and T.B. Clarkson Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys Menopause 6 2002 422 429
45. Suparto ICH, J.K. Williams, J.M. Cline, M.S. Anthony, and J.L. Fox Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys Am J Obstet Gynecol 188 2003 1132 1140
46. R.B. Clarke Human breast cell proliferation and its relationship to steroid receptor expression Climacteric 7 2004 129 137
47. O.M. Conneely, B.M. Jericevic, and J.P. Lydon Progesterone receptors in mammary gland development and tumorigenesis J Mammary Gland Biol Neoplasia 8 2003 205 214
48. P. Roger, M.E. Sahla, S. Mäkelä, J.A. Gustafsson, P. Baldet, and H. Rochefort Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors Cancer Res 61 2001 2537 2541
49. S.A. Fuqua, R. Schiff, and I. Parra Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters Cancer Res 2003 2434 2439
50. G. Dontu, D. El-Ashry, and M.S. Wicha Breast cancer, stem/progenitor cells and the estrogen receptor Trends Endocrinol Metab 15 2004 193 197
51. G.A. Bray Medical consequences of obesity J Clin Endocrinol Metab 89 2004 2583 2589
52. S.Y. Pan, K.C. Johnson, and A.M. Ugnat Association of obesity and cancer risk in Canada Am J Epidemiol 159 2004 259 268
53. D.V. Schapira, R.A. Clark, P.A. Wolff, A.R. Jarrett, N.B. Kumar, and N.M. Aziz Visceral obesity and breast cancer risk Cancer 74 1994 632 639
54. P.H. Lahmann, L. Lissner, B. Gullberg, H. Olsson, and G. Berglund A prospective study of adiposity and postmenopausal breast cancer risk: the Malmö diet and cancer study Int J Cancer 103 2003 246 252
55. P.H. Lahmann, K. Hoffmann, and N. Allen Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC) Int J Cancer 111 2004 762 771
56. P.G. Toniolo, M. Levitz, and A. Zeleniuch-Jacquotte A prospective study of endogenous estrogens and breast cancer in postmenopausal women J Natl Cancer Inst 87 1995 190 197
57. H.V. Thomas, T.J. Key, and D.S. Allen A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey Br J Cancer 76 1997 401 405
58. J.A. Cauley, F.L. Lucas, and L.H. Kuller Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer Ann Intern Med 130 1999 270 277
59. B.A. Stoll Upper abdominal obesity, insulin resistance and breast cancer risk Int J Obesity 26 2002 747 753
60. S.R. Lindheim, S.C. Presser, E.C. Ditkoff, M.A. Vijod, F.Z. Stanczyk, and R.A. Lobo A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin Fertil Steril 60 1993 664 667
61. M.C. Carr The emergence of the metabolic syndrome with menopause J Clin Endocrinol Metab 88 2003 2404 2411
62. N. Stefan, B. Vozarova, and T. Funahashi Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans Diabetes 2002 1884 1888
63. C. Weyer, T. Funahashi, and S. Tanaka Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia J Clin Endocrinol Metab 2001 1930 1935
64. C. Mantzoros, E. Petridou, and N. Dessypris Adiponectin and breast cancer risk J Clin Endocrinol Metab 89 2004 1102 1107
65. C. Schairer, D. Hill, and S.R. Sturgeon Serum concentrations of IGF-1, IGFBP-3 and C-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women Int J Cancer 108 2004 773 779
66. K.B. Michels, C.G. Solomon, and F.B. Hu Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study Diabetes Care 26 2003 1752 1758
67. M.D. Brown, M.T. Korytkowski, J.M. Zmuda, S.D. McCole, G.E. Moore, and J.M. Hagberg Insulin sensitivity in postmenopausal women Diabetes Care 23 2000 1731 1736
68. M.A. Espeland, P.E. Hogan, and S.E. Fineberg Effect of postmenopausal hormone therapy on glucose and insulin concentrations Diabetes Care 21 1998 1589 1595
69. H. Sumino, S. Ichikawa, and H. Itoh Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance Horm Res 60 2003 134 142
70. M.M. Gelfand, P. Fugere, and F. Bissonnette Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding Menopause 4 1997 10 18
71. K.L. Margolis, D.E. Bonds, and R.J. Rodabough Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial Diabetologia 47 2004 1175 1187
72. H. Kuhl Is the elevated breast cancer risk observed in the WHI study an artifact? (letter to the editor) Climacteric 7 2004 319 323
73. G.A. Colditz, S.E. Hankinson, and D.J. Hunter The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N Engl J Med 332 1995 1589 1593
74. Endogenous Hormones and Breast Cancer Collaborative Group Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women J Natl Cancer Inst 95 2003 1218 1226
75. Z. Huang, S.E. Hankinson, and G.A. Colditz Dual effects of weight and weight gain on breast cancer risk JAMA 278 1997 1407 1411
76. I. Romieu, E. Lazcano-Ponce, L.M. Sanchez-Zamorano, W. Willett, and M. Hernandez-Avila Carbohydrates and the risk of breast cancer among Mexican women Cancer Epidemiol Biomark Prev 13 2004 1283 1289
77. Augustin LSA, L. Dal Maso, and C. La Vecchia Dietary glycemic index and glycemic load, and breast cancer risk: a case-control study Ann Oncol 12 2001 1533 1538
78. M.J. Borugian, S.B. Sheps, and C. Kim-Sing Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomark Prevdkjdot 13 2004 1163 1172
79. H.J. Thrompson, Z. Zhu, and W. Jiang Dietary energy restriction in breast cancer prevention J Mammary Gland Biol Neoplasia 8 2003 133 142
80. A. Trentham-Dietz, P.A. Newcomb, and K.M. Egan Weight change and risk of postmenopausal breast cancer (United States) Cancer Causes Contr 11 2000 533 542
81. C.L. Rock Diet and breast cancer: can dietary factors influence survival? J Mammary Gland Biol Neoplasia 8 2003 119 132
82. D. Kirpichnikov, S.I. McFarlane, and J.R. Sowers Metformin: an update Ann Intern Med 137 2002 25 33
83. N. Biglia, E. Defabiani, R. Ponzone, L. Mariani, D. Marenco, and P. Sismondi Management of risk of breast carcinoma in postmenopausal women Endocrine-related Cancer 11 2004 69 83
84. H.O. Adami, G. Adams, and P. Boyle Breast-cancer etiology Int J Cancer Suppl 5 1990 22 39
85. J.M. Dixon, C. McDonald, R.A. Elton, and W.R. Miller Risk of breast cancer in women with palpable breast cysts: a prospective study Lancet 353 1999 1742 1745
86. A. Gayet, J. Esteve, B. Seradour, L. Piana, and J. Jacquemier Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign Eur J Cancer 39 2003 1738 1745
87. G. Plu-Bureau, M.G. Le, R. Sitruk-Ware, J.C. Thalabard, and Mauvais-Jarvis Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease Br J Cancer 70 1994 270 277
88. H. Madjar, M. Vetter, H. Prömpeler, M. Breckwoldt, and A. Pfleiderer Doppler measurement of breast vascularity in women under pharmacologic treatment of benign breast disease J Reprod Med 38 1993 935 940
89. N.F. Boyd, H.M. Jensen, G. Cooke, H. Lee Han, and G.A. Lockwood Mammographic densities and the prevalence and incidence of histological types of benign disease Eur J Cancer Prev 9 2000 15 24
90. S. Alowami, S. Troup, S. Al-Haddad, I. Kirkpatrick, and P.H. Watson Mammographic density is related to stroma and stromal proteoglycan expression Breast Cancer Res 5 2003 R129 R135
91. W.H. Wong, R.I. Freedman, N.E. Levan, C. Hyman, and E.J. Quilligan Changes in the capillary filtration coefficient of cutaneous vessels in women with premenstrual tension Am J Obstet Gynecol 114 1972 950 953
92. N. Colacurci, F. Fornaro, P. de Franciscis, D. Mele, M. Palermo, and W. del Vecchio Effects of a short-term suspension of hormone replacement therapy on mammographic density Fertil Steril 76 2001 451 455
93. J.F. Trabal, J.P. Lenihan, and T.E. Melchione Low-dose unopposed estrogens: preliminary findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period Menopause 4 1997 130 138
94. M. Notelovitz, R.E. Varner, and R.W. Reaber Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens Menopause 4 1997 80 88
95. K.L. Cushing, N.S. Weiss, L.F. Voigt, B. McKnight, and SA.A. Beresford Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens Obstet Gynecol 91 1998 35 39
96. Meuwissen JHJM, H. van Langen, E. Moret, and I. Navarro-Morquecho Monitoring of oestrogen replacement therapy by vaginosonography of the endometrium Maturitas 15 1992 33 37
97. Meuwissen JHJM, B.J. Oddens, and PJJ.M. Klinkhamer Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed oestrogen use Maturitas 24 1996 21 30
98. B. Ettinger, J. Selby, J.T. Citron, A. Vangessel, V.M. Ettinger, and M.R. Hendrickson Cyclic hormone replacement therapy using quarterly progestin Obstet Gynecol 83 1994 693 700
99. E. Hirvonen, T. Salmi, and J. Puolakka Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 21 1995 39 44
100. P.J. Boerrigter, PHM van de Weijer, JPA Baak, H. Fox, A.A. Haspels, and P. Kenemans Endometrial response in estrogen replacement therapy quarterly combined with a progestogen Maturitas 24 1996 63 71
101. A.B. Pinto, E.F. Binder, W.M. Kohrt, D.R. Bronder, and D.B. Williams Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot study Am J Obstet Gynecol 189 2003 11 15
102. R. Erkkola, U. Kumento, S. Lehmuskoski, L. Mattila, and M. Mustonen No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years J Br Menopause Soc 10 2004 9 13
103. K. Bjarnason, A. Cerin, R. Lindgren, and T. Weber Adverse endometrial effects during long cycle hormone replacement therapy Maturitas 32 1999 161 170
104. E. Pukkala, A. Tulenheimo-Silfvast, and A. Leminen Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997 Cancer Causes Contr 12 2001 111 115